Medtronic (NYSE:MDT) said yesterday it launched a pilot study of its investigational Extravascular Implantable cardioverter defibrillator system, with the first patient implant already performed at New Zealand’s Christchurch Hospital.
The Fridley, Minn.-based company’s EV ICD system uses leads placed outside of the heart and veins to provide both defibrillation and antitachycardia pacing therapy. The initial implantation marks the first long-term use of the EV ICD system, the company said.
